Correlation between SACE (Subjective Angiographic Chemoembolization Endpoint) score and tumor response and its impact on survival after DEB-TACE in patients with hepatocellular carcinoma
- 51 Downloads
To asses angiographic and computed tomographic success criteria during and after transcatheter arterial drug-eluting bead chemoembolization (DEB-TACE) in patients with hepatocellular carcinoma (HCC) and its impact on progression-free survival (PFS) and overall survival (OS).
In this retrospective single-center study, 50 patients with unresectable HCC having undergone DEB-TACE from January 2010 to July 2015 were assessed. The angiographic endpoint was classified by Subjective Angiographic Chemoembolization Endpoint (SACE) scale. Relative tumor density in arterial (DArt) and portal venous phase (DPV) computed tomography post- versus pre-DEB-TACE were calculated, respectively. Tumor response according to modified Response Criteria in Solid Tumors (mRECIST) was assessed. Univariate Kaplan–Meier and Cox regression analysis were carried out.
SACE scores I, II, III, and IV were found in 1 (2%), 20 (40%), 15 (30%), and 14 (28%) patients, respectively. Median OS and PFS were 14.2 and 5.5 months, respectively. Death rates at 6 months, 1 year and 2 years were 24%, 38%, and 52%, respectively. SACE score during DEB-TACE significantly correlated with local and overall mRECIST results (local: p < 0.001, r = 0.49, overall: p = 0.042, r = 0.29) and inversely correlated with DPV (p = 0.005, r = − 0.40). In univariate analysis, progressive disease (PD) according to mRECIST and increase of DArt and DPV were associated with significantly shorter PFS. Modified RECIST independently predicted OS (hazard ratio for complete remission vs. PD = 0.15, 95% confidence interval 0.03–0.68, p = 0.014).
A direct impact of SACE on PFS or OS could not be shown. However, SACE significantly correlated with local and overall mRECIST tumor response that again significantly predicted OS. We therefore postulate an indirect impact of SACE on OS. Consequently, complete embolization should be attempted.
KeywordsHepatocellular carcinoma Transcatheter arterial drug-eluting bead chemoembolization TACE Subjective Angiographic Chemoembolization Endpoint scale SACE Tumor density mRECIST
The authors would like to thank PD Dr. Med. Bruno Neuner, Campus Virchow-Hospital, Charité Berlin, as well as Sebastian Häckl and Florian Lasch, Institute for Biometry, Hannover Medical School for their statistical guidance throughout the study.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
This study was reviewed and approved by the Ethical Committee of Hannover Medical School, Germany.
- 2.Stuver S TD (2008) Cancer of the Liver and Biliary Tract. In: Adami HO, Hunter D, Trichopoulos D, editors Textbook of Cancer Epidemiology 2nd ed New York:. https://doi.org/10.1093/acprof:oso/9780195311174.003.0012
- 6.Varela M, Real MI, Burrel M, Forner A, Sala M, Brunet M, Ayuso C, Castells L, Montana X, Llovet JM, Bruix J (2007) Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. Journal of hepatology 46 (3):474–481. https://doi.org/10.1016/j.jhep.2006.10.020 CrossRefGoogle Scholar
- 7.Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A, Pitton M, Sergent G, Pfammatter T, Terraz S, Benhamou Y, Avajon Y, Gruenberger T, Pomoni M, Langenberger H, Schuchmann M, Dumortier J, Mueller C, Chevallier P, Lencioni R, Investigators PV (2010) Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovascular and interventional radiology 33 (1):41–52. https://doi.org/10.1007/s00270-009-9711-7 CrossRefGoogle Scholar
- 8.Sacco R BI, Bertini M, Bozzi E, Romano A, Petruzzi P, Tumino E, Ginanni B, Federici G, Cioni R. (2011) Conventional versus doxorubicin-eluting bead transarterial chemoembolization for hepatocellular carcinoma. J Vasc Interv Radiol 22:1545–1552. doi: https://doi.org/10.1016/j.jvir.2011.07.002 CrossRefGoogle Scholar
- 9.Dhanasekaran R, Kooby DA, Staley CA, Kauh JS, Khanna V, Kim HS (2010) Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocelluar carcinoma (HCC). Journal of surgical oncology 101 (6):476–480. https://doi.org/10.1002/jso.21522 Google Scholar
- 11.Kloeckner R, Weinmann A, Prinz F, Pinto dos Santos D, Ruckes C, Dueber C, Pitton MB (2015) Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma. BMC cancer 15:465. https://doi.org/10.1186/s12885-015-1480-x CrossRefGoogle Scholar
- 12.Golfieri R, Giampalma E, Renzulli M, Cioni R, Bargellini I, Bartolozzi C, Breatta AD, Gandini G, Nani R, Gasparini D, Cucchetti A, Bolondi L, Trevisani F (2014) Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. British journal of cancer. https://doi.org/10.1038/bjc.2014.199
- 14.Shim JH, Lee HC, Kim SO, Shin YM, Kim KM, Lim YS, Suh DJ (2012) Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models. Radiology 262 (2):708–718. https://doi.org/10.1148/radiol.11110282 CrossRefGoogle Scholar
- 15.Barman PM, Sharma P, Krishnamurthy V, Willatt J, McCurdy H, Moseley RH, Su GL (2014) Predictors of Mortality in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. Digestive diseases and sciences. https://doi.org/10.1007/s10620-014-3247-7
- 16.Han K, Kim JH, Yoon HM, Kim EJ, Gwon DI, Ko GY, Yoon HK, Ko HK (2014) Transcatheter arterial chemoembolization for infiltrative hepatocellular carcinoma: clinical safety and efficacy and factors influencing patient survival. Korean J Radiol 15 (4):464–471. https://doi.org/10.3348/kjr.2014.15.4.464 CrossRefGoogle Scholar
- 17.Kwan SW, Fidelman N, Ma E, Kerlan RK, Jr., Yao FY (2012) Imaging predictors of the response to transarterial chemoembolization in patients with hepatocellular carcinoma: a radiological-pathological correlation. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 18 (6):727–736. https://doi.org/10.1002/lt.23413 CrossRefGoogle Scholar
- 18.Choi H, Charnsangavej C, de Castro Faria S, Tamm EP, Benjamin RS, Johnson MM, Macapinlac HA, Podoloff DA (2004) CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. AJR American journal of roentgenology 183 (6):1619–1628. https://doi.org/10.2214/ajr.183.6.01831619 CrossRefGoogle Scholar
- 19.Beuzit L, Edeline J, Brun V, Ronot M, Guillygomarc’h A, Boudjema K, Gandon Y, Garin E, Rolland Y (2016) Comparison of Choi criteria and Response Evaluation Criteria in Solid Tumors (RECIST) for intrahepatic cholangiocarcinoma treated with glass-microspheres Yttrium-90 selective internal radiation therapy (SIRT). European journal of radiology 85 (8):1445–1452. https://doi.org/10.1016/j.ejrad.2016.05.020 CrossRefGoogle Scholar
- 20.Imai N, Katano Y, Kuzuya T, Honda T, Hayashi K, Ishigami M, Itoh A, Hirooka Y, Goto H (2013) An increase in lesion density can predict lower local recurrence after transarterial chemoembolization in patients with hepatocellular carcinoma. Hepato-gastroenterology 60 (125):965–970. https://doi.org/10.5754/hge121229 Google Scholar
- 21.Bryant MK, Dorn DP, Zarzour J, Smith JK, Redden DT, Saddekni S, Abdel Aal AK, Gray SH, Eckhoff DE, Dubay DA (2014) Computed tomography predictors of hepatocellular carcinoma tumour necrosis after chemoembolization. HPB : the official journal of the International Hepato Pancreato Biliary Association 16 (4):327–335. https://doi.org/10.1111/hpb.12149 CrossRefGoogle Scholar
- 23.Lewandowski RJ, Wang D, Gehl J, Atassi B, Ryu RK, Sato K, Nemcek AA, Jr., Miller FH, Mulcahy MF, Kulik L, Larson AC, Salem R, Omary RA (2007) A comparison of chemoembolization endpoints using angiographic versus transcatheter intraarterial perfusion/MR imaging monitoring. Journal of vascular and interventional radiology : JVIR 18 (10):1249–1257. https://doi.org/10.1016/j.jvir.2007.06.028 CrossRefGoogle Scholar
- 24.de Korompay N, Alshammari M, Klass D, Chou FY, Chung J, Ho S, Liu DM (2018) Intraprocedural Parenchymal Blood Volume Is a Predictor of Treatment Response for Chemoembolization in Hepatocellular Carcinoma: Results of a Prospective Study. Journal of vascular and interventional radiology : JVIR 29 (7):928–935. https://doi.org/10.1016/j.jvir.2018.01.783 CrossRefGoogle Scholar
- 27.Wiggermann P, Sieron D, Brosche C, Brauer T, Scheer F, Platzek I, Wawrzynek W, Stroszczynski C (2011) Transarterial Chemoembolization of Child-A hepatocellular carcinoma: drug-eluting bead TACE (DEB TACE) vs. TACE with cisplatin/lipiodol (cTACE). Medical science monitor: international medical journal of experimental and clinical research 17 (4):CR189-195Google Scholar
- 28.Song MJ, Chun HJ, Song DS, Kim HY, Yoo SH, Park CH, Bae SH, Choi JY, Chang UI, Yang JM, Lee HG, Yoon SK (2012) Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma. Journal of hepatology 57 (6):1244–1250. https://doi.org/10.1016/j.jhep.2012.07.017 CrossRefGoogle Scholar
- 29.Ronot M, Bouattour M, Wassermann J, Bruno O, Dreyer C, Larroque B, Castera L, Vilgrain V, Belghiti J, Raymond E, Faivre S (2014) Alternative Response Criteria (Choi, European association for the study of the liver, and modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in patients with advanced hepatocellular carcinoma treated with sorafenib. The oncologist 19 (4):394–402. https://doi.org/10.1634/theoncologist.2013-0114
- 30.Larson AC, Wang D, Atassi B, Sato KT, Ryu RK, Lewandowski RJ, Nemcek AA, Jr., Mulcahy MF, Kulik LM, Miller FH, Salem R, Omary RA (2008) Transcatheter intraarterial perfusion: MR monitoring of chemoembolization for hepatocellular carcinoma–feasibility of initial clinical translation. Radiology 246 (3):964–971. https://doi.org/10.1148/radiol.2463070725 CrossRefGoogle Scholar
- 31.Jin B, Wang D, Lewandowski RJ, Ryu RK, Sato KT, Larson AC, Salem R, Omary RA (2011) Quantitative 4D transcatheter intraarterial perfusion MRI for standardizing angiographic chemoembolization endpoints. AJR American journal of roentgenology 197 (5):1237–1243. https://doi.org/10.2214/ajr.10.5821 CrossRefGoogle Scholar
- 34.Wang J, Cheng JJ, Huang KY, Zhuang ZG, Zhang XB, Chi JC, Hua XL, Xu JR (2016) Quantitative assessment of angiographic perfusion reduction using color-coded digital subtraction angiography during transarterial chemoembolization. Abdom Radiol (NY) 41 (3):545–552. https://doi.org/10.1007/s00261-015-0622-6 CrossRefGoogle Scholar
- 35.Cohen J, Cohen J (2003) Applied multiple regression/correlation analysis for the behavioral sciences. 3rd edn. L. Erlbaum Associates, Mahwah, N.J.Google Scholar